We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
- Authors
Zhu, Li; Liao, Shanmei; Child, Michael; Zhang, Jenny; Persson, Anna; Sevinsky, Heather; Eley, Timothy; Xu, Xiaohui; Krystal, Mark; Farajallah, Awny; McGrath, Donnie; Molina, Jean-Michel; Bertz, Richard
- Abstract
Objectives To characterize the pharmacokinetics and inhibitory quotient (IQ) of atazanavir/ritonavir- and lopinavir/ritonavir-based regimens in HIV-infected, treatment-naive patients. Methods The CASTLE Study was a 96 week randomized study comparing 300 mg of atazanavir once daily with 400 mg of lopinavir twice daily, each with low-dose ritonavir (100 mg) plus tenofovir disoproxil fumarate/emtricitabine in HIV-infected, treatment-naive patients. A subset of patients participated in an intensive pharmacokinetic evaluation of the atazanavir regimen (n = 18) and the lopinavir regimen (n = 21) at week 4. (ClinicalTrials.gov NCT00272779) Results Atazanavir geometric mean (CV%) Cmax, Cmin and AUC over the dosing interval were 2897 (46) ng/mL, 526 (57) ng/mL and 28 605 (46) ng · h/mL, respectively, and for lopinavir they were 10 655 (51) ng/mL, 5944 (68) ng/mL and 90 946 (59) ng · h/mL, respectively. The baseline protein binding-adjusted 90% effective concentration (PBA-EC90) was 16 (44) ng/mL for atazanavir and 173 (44) ng/mL for lopinavir. The median IQ (min, max), calculated as the ratio of Cmin to individual baseline PBA-EC90, was 35 (4, 77) for atazanavir and 34 (11, 129) for lopinavir. The Cmax for ritonavir was 46% higher, while AUC0–24 and Cmin were 16% and 72% lower in the atazanavir regimen compared with the lopinavir regimen. Tenofovir exposures were similar with both treatments. Conclusions Atazanavir (300 mg once daily) and lopinavir (400 mg twice daily), each with low-dose ritonavir, achieved similar IQs in HIV-infected, treatment-naive patients. These results are supportive of the main clinical finding of the CASTLE Study, that the atazanavir/ritonavir-based regimen is non-inferior in antiviral efficacy to the lopinavir/ritonavir-based regimen in antiretroviral-naive subjects.
- Subjects
PHARMACOKINETICS; ATAZANAVIR; CLINICAL pharmacology; HIV-positive persons; PROTEASE inhibitors
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2012, Vol 67, Issue 2, p465
- ISSN
0305-7453
- Publication type
Article
- DOI
10.1093/jac/dkr490